Evidence map›Paper›PMID 37406934›Full record

ArticleVirus research2023

First sequenced cases of Omicron BA.2 sublineage in Ecuador.

D A Andrade-Molina, G A Morey-León, K E Muñoz-Mawyin, F F Cruz-Fatuly, J C Fernández-Cadena, P Cárdenas

Open access · goldAbstract read
In one paragraph

Article in Virus research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

D A Andrade-MolinaOmics Sciences Laboratory, Faculty of Health Sciences, Universidad Espíritu Santo, Samborondón, Ecuador. Electronic address: dmandrademolina@uees.edu.ec.
G A Morey-LeónFaculty of Health Sciences, Universidad de Guayaquil, Guayaquil, Ecuador.
K E Muñoz-MawyinOmics Sciences Laboratory, Faculty of Health Sciences, Universidad Espíritu Santo, Samborondón, Ecuador.
F F Cruz-FatulyOmics Sciences Laboratory, Faculty of Health Sciences, Universidad Espíritu Santo, Samborondón, Ecuador.
J C Fernández-CadenaLaboratorios INTERLAB, Guayaquil, Ecuador.
P CárdenasInstitute of Microbiology, Universidad San Francisco de Quito, Quito, Ecuador.
Universidad de Especialidades Espíritu Santo · ECUniversity of Guayaquil · ECUniversidad San Francisco de Quito · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The largest wave of infection with SARS-CoV-2 virus in Ecuador was observed in mid-December 2021 and early January 2022, driven by B.1.1.529/BA (Omicron) variant. During the second half of March, an increase in the number of daily cases was observed and coincided with the emergence of the BA.2 variant, which we describe in the present study. The first sequenced five cases of SARS-CoV-2 21L/BA.2 in Ecuador were identified using variant specific genotyping by qPCR and confirmed by whole genome sequencing (WGS). The first sequenced Ecuadorian BA.2 isolate was obtained from a person with international travel history who became symptomatic 3 days after travelling, whereas in the other cases no travel history was recorded.

Indexed as

COVID-19Base SequenceEcuadorHumansSARS-CoV-2Whole Genome SequencingBA.2EcuadorOmicronSARS-CoV-2

Identifiers

PMID37406934
PMCPMC10410591
OpenAlexW4383065575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.